BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pramoolsinsup C. Management of viral hepatitis B. J Gastroenterol Hepatol. 2002;17 Suppl:S125-S145. [PMID: 12000599 DOI: 10.1046/j.1440-1746.17.s1.3.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Hilleman MR. Critical overview and outlook: pathogenesis, prevention, and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus. Vaccine. 2003;21:4626-4649. [PMID: 14585670 DOI: 10.1016/s0264-410x(03)00529-2] [Cited by in Crossref: 61] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
2 Ze E, Baek EK, Lee JJ, Chung HW, Ahn DG, Cho HJ, Kwon JC, Kim HJ, Lee H. Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir. Clin Mol Hepatol 2014;20:267-73. [PMID: 25320730 DOI: 10.3350/cmh.2014.20.3.267] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
3 Kurita T, Kitaichi T, Nagao T, Miura T, Kitazono Y. Safety analysis of Epzicom® (lamivudine/abacavir sulfate) in post-marketing surveillance in Japan. Pharmacoepidemiol Drug Saf 2014;23:372-81. [PMID: 24590575 DOI: 10.1002/pds.3588] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
4 Pei F, Ning JY, You JF, Yang JP, Zheng J. YMDD variants of HBV DNA polymerase gene: rapid detection and clinicopathological analysis with long-term lamivudine therapy after liver transplantation. World J Gastroenterol 2005;11:2714-9. [PMID: 15884109 DOI: 10.3748/wjg.v11.i18.2714] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
5 Thomas C, Nelson M, Stebbing J. HIV and Hepatitis B: A Review. AIDS Patient Care and STDs 2003;17:623-33. [DOI: 10.1089/108729103771928681] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
6 Lawrance IC, Murray K, Hall A, Sung JJ, Leong R. A prospective comparative study of ASCA and pANCA in Chinese and Caucasian IBD patients. Am J Gastroenterol. 2004;99:2186-2194. [PMID: 15555001 DOI: 10.1111/j.1572-0241.2004.40486.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 3.0] [Reference Citation Analysis]
7 Zhao Y, Yu Y, Ye L. MiR-3613-3p impairs IFN-induced immune response by targeting CMPK1 in chronic hepatitis B. Infect Genet Evol 2019;74:103919. [PMID: 31201869 DOI: 10.1016/j.meegid.2019.103919] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Kim MN, Lee CK, Ahn SH, Lee S, Kim SU, Kim DY, Kim HS, Han KH, Chon CY, Park JY. Maintaining remission in lamivudine-resistant patients with a virological response to adefovir add-on lamivudine after stopping lamivudine therapy. Liver Int 2014;34:1543-9. [PMID: 24330475 DOI: 10.1111/liv.12437] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
9 Wang Y, Li Y. miR-146 promotes HBV replication and expression by targeting ZEB2. Biomed Pharmacother. 2018;99:576-582. [PMID: 29902868 DOI: 10.1016/j.biopha.2018.01.097] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
10 Choi SH, Yang KJ, Lee DS. Effects of Complementary Combination Therapy of Korean Red Ginseng and Antiviral Agents in Chronic Hepatitis B. J Altern Complement Med 2016;22:964-9. [PMID: 27603149 DOI: 10.1089/acm.2015.0206] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
11 Qaqish RB, Mattes KA, Ritchie DJ. Adefovir dipivoxil: A new antiviral agent for the treatment of hepatitis B virus infection. Clinical Therapeutics 2003;25:3084-99. [DOI: 10.1016/s0149-2918(03)90093-2] [Cited by in Crossref: 35] [Cited by in F6Publishing: 2] [Article Influence: 1.9] [Reference Citation Analysis]
12 Gibb R, Nimmo GR, O'loughlin P, Lowe P, Drummond D. Detection of HBsAg mutants in a population with a low prevalence of hepatitis B virus infection. J Med Virol 2007;79:351-5. [DOI: 10.1002/jmv.20823] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
13 Wang J, Qu X, Qi Y, Li J, Song X, Li L, Yin D, Xu K, Li J. Pharmacokinetics of anti-HBV polyoxometalate in rats. PLoS One 2014;9:e98292. [PMID: 24921932 DOI: 10.1371/journal.pone.0098292] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
14 Demetris A, Nalesnik M, Randhawa P, Wu T, Minervini M, Lai C, Lu Z. Histological Patterns of Rejection and Other Causes of Liver Dysfunction. Transplantation of the Liver. Elsevier; 2005. pp. 1057-128. [DOI: 10.1016/b978-0-7216-0118-2.50074-4] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
15 Yu H, Hou Z, Han Q, Zhang C, Zhang J. The anti-HBV effect mediated by a novel recombinant eukaryotic expression vector for IFN-α. Virol J 2013;10:270. [PMID: 23984795 DOI: 10.1186/1743-422X-10-270] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
16 Ryu K, Kim ND, Choi SI, Han CK, Yoon JH, No KT, Kim KH, Seong BL. Identification of novel inhibitors of HCV RNA-dependent RNA polymerase by pharmacophore-based virtual screening and in vitro evaluation. Bioorg Med Chem 2009;17:2975-82. [PMID: 19332375 DOI: 10.1016/j.bmc.2009.03.024] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
17 Park JH, Lee MK, Kim HS, Kim KL, Cho EW. Targeted destruction of the polymerized human serum albumin binding site within the preS2 region of the HBV surface antigen while retaining full immunogenicity for this epitope. J Viral Hepat. 2003;10:70-79. [PMID: 12558915 DOI: 10.1046/j.1365-2893.2003.00397.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
18 He Q, Li W, Ren J, Huang Y, Hu Q, Chen J, Chen W. ZEB2 inhibits HBV transcription and replication by targeting its core promoter. Oncotarget. 2016;7:16003-16011. [PMID: 26895378 DOI: 10.18632/oncotarget.7435] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
19 Lee CH, Kim SO, Byun KS, Moon MS, Kim EO, Yeon JE, Yoo W, Hong SP. Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough. Gastroenterology 2006;130:1144-52. [PMID: 16618409 DOI: 10.1053/j.gastro.2006.01.005] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
20 Huang ZM, Huang QW, Qin YQ, He YZ, Qin HJ, Zhou YN, Xu X, Huang MJ. YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines. World J Gastroenterol. 2005;11:867-870. [PMID: 15682483 DOI: 10.3748/wjg.v11.i6.867] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 29] [Article Influence: 1.7] [Reference Citation Analysis]
21 Li X, Liu X, Tian L, Chen Y. Cytokine-Mediated Immunopathogenesis of Hepatitis B Virus Infections. Clin Rev Allergy Immunol. 2016;50:41-54. [PMID: 25480494 DOI: 10.1007/s12016-014-8465-4] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 8.2] [Reference Citation Analysis]
22 Busca A, Kumar A. Innate immune responses in hepatitis B virus (HBV) infection. Virol J. 2014;11:22. [PMID: 24507433 DOI: 10.1186/1743-422x-11-22] [Cited by in Crossref: 79] [Cited by in F6Publishing: 48] [Article Influence: 11.3] [Reference Citation Analysis]
23 Lu LG, Zeng MD, Mao YM, Li JQ, Wan MB, Li CZ, Chen CW, Fu QC, Wang JY, She WM. Oxymatrine therapy for chronic hepatitis B: a randomized double-blind and placebo-controlled multi-center trial. World J Gastroenterol. 2003;9:2480-2483. [PMID: 14606080 DOI: 10.3748/wjg.v9.i11.2480] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 49] [Article Influence: 2.8] [Reference Citation Analysis]
24 Mansourian PG, Ghany MG, Thomas E. Spontaneous Mutations in the HBV Genome and their Clinical Implications. Curr Hepatitis Rep 2013;12:79-87. [DOI: 10.1007/s11901-013-0170-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Nanashima A, Tanaka K, Yamaguchi H, Shibasaki S, Morino S, Yoshinaga M, Sawai T, Nakagoe T, Ayabe H. Fibrosis and inflammatory activity in noncancerous tissue and mitotic index of cancer tissue in patients with hepatocellular carcinoma: relationship to clinicopathological factors and prognosis after hepatic resection. Dig Dis Sci. 2003;48:1517-1522. [PMID: 12924646 DOI: 10.1023/A:1024759606402] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
26 Levy AR, Kowdley KV, Iloeje U, Tafesse E, Mukherjee J, Gish R, Bzowej N, Briggs AH. The Impact of Chronic Hepatitis B on Quality of Life: A Multinational Study of Utilities from Infected and Uninfected Persons. Value in Health 2008;11:527-38. [DOI: 10.1111/j.1524-4733.2007.00297.x] [Cited by in Crossref: 99] [Cited by in F6Publishing: 78] [Article Influence: 7.6] [Reference Citation Analysis]
27 Neff GW, Sherman KE. Post-transplant hepatitis: HCV and HBV. Curr hepatitis rep 2004;3:98-104. [DOI: 10.1007/s11901-004-0016-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
28 Peters MG, Hann H, Martin P, Heathcote E, Buggisch P, Rubin R, Bourliere M, Kowdley K, Trepo C, Gray D, Sullivan M, Kleber K, Ebrahimi R, Xiong S, Brosgart CL. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B 1 1The Adefovir Dipivoxil International 461 Study Group includes the following: N. Afdhal (Beth Israel Deaconess Medical Center, Boston, MA); P. Angus (Austin and Repatriation Medical Centre, Melbourne, Australia); Y. Benhamou (Hopital La Pitie Salpetriere, Paris, France); M. Bourliere (Hopital Saint Joseph, Marseille, France); P. Buggisch (Universitaetsklinikum Eppendorf, Department of Medicine, Hamburg, Germany); P. Couzigou (Hopital Haut Leveque, Pessac, France); P. Ducrotte and G. Riachi (Hopital Charles Nicolle, Rouen, France); E. Jenny Heathcote (Toronto Western Hospital, Toronto, Ontario, Canada); H. W. Hann (Jefferson Medical College, Philadelphia, PA); I. Jacobson (New York Presbyterian Hospital, New York, NY); K. Kowdley (University of Washington Hepatology Center, Seattle, WA); P. Marcellin (Hopital Beaujon, Clichy, France); P. Martin (Cedars-Sinai Medical Center, Los Angeles, CA); J. M. Metreau (Centre Hospitalier Universitaire Henri Mondor, Creteil, France); M. G. Peters (University of California, San Francisco, San Francisco, CA); R. Rubin (Piedmont Hospital, Atlanta, GA); S. Sacks (Viridae Clinical Sciences, Inc., Vancouver, Canada); H. Thomas (St. Mary’s Hospital, London, England); C. Trepo (Hopital Hôtel Dieu, Lyon, France); D. Vetter (Hopital Civil, Strasbourg, France); C. L. Brosgart, R. Ebrahimi, J. Fry, C. Gibbs, K. Kleber, J. Rooney, M. Sullivan, P. Vig, C. Westland, M. Wulfsohn, and S. Xiong (Gilead Sciences, Inc., Foster City, CA); D. F. Gray (GlaxoSmithKline, Greenford, Middlesex, England); R. Schilling and V. Ferry (Parexel International, Waltham, MA); and D. Hunt (Covance Laboratories, Princeton, NJ). Gastroenterology 2004;126:91-101. [DOI: 10.1053/j.gastro.2003.10.051] [Cited by in Crossref: 406] [Cited by in F6Publishing: 331] [Article Influence: 23.9] [Reference Citation Analysis]
29 Motavaf M, Motavaf M, Alavian SM, Alavian SM. RNA Interference: A Promising Approach for the Treatment of Viral Hepatitis. Hepat Mon 2012;12:7-8. [DOI: 10.5812/hepatmon.4294] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
30 Huang ZM, Huang QW, Qin YQ, Huang CH, Qin HJ, Zhou YN, Xu X, Lu CL. Clinical characteristics and distribution of hepatitis B virus genotypes in Guangxi Zhuang population. World J Gastroenterol 2005;11:6525-9. [PMID: 16425428 DOI: 10.3748/wjg.v11.i41.6525] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
31 Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV. Global epidemiology of hepatitis B virus. J Clin Gastroenterol. 2004;38:S158-S168. [PMID: 15602165 DOI: 10.1097/00004836-200411003-00008] [Cited by in Crossref: 362] [Cited by in F6Publishing: 347] [Article Influence: 22.6] [Reference Citation Analysis]
32 Yeo W, Mo FK, Chan SL, Leung NW, Hui P, Lam WY, Mok TS, Lam KC, Ho WM, Koh J, Tang JW, Chan AT, Chan PK. Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy. Hepatology 2007;45:1382-9. [PMID: 17539025 DOI: 10.1002/hep.21572] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 3.4] [Reference Citation Analysis]
33 Jain A, Fung J. Advances in hepatitis B virus infection. Transplantation Proceedings 2003;35:342-4. [DOI: 10.1016/s0041-1345(02)03996-9] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
34 Montalbano M, Neff GW. Management of recurrent viral hepatitis B and C after liver transplantation. Curr Gastroenterol Rep 2006;8:60-6. [PMID: 16510036 DOI: 10.1007/s11894-006-0065-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
35 Poultsides LA, Ma Y, Della Valle AG, Chiu YL, Sculco TP, Memtsoudis SG. In-hospital surgical site infections after primary hip and knee arthroplasty--incidence and risk factors. J Arthroplasty. 2013;28:385-389. [PMID: 23142444 DOI: 10.1016/j.arth.2012.06.027] [Cited by in Crossref: 105] [Cited by in F6Publishing: 83] [Article Influence: 11.7] [Reference Citation Analysis]
36 Yeo W, Lam K, Zee B, Chan P, Mo F, Ho W, Wong W, Leung T, Chan A, Ma B, Mok T, Johnson P. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Annals of Oncology 2004;15:1661-6. [DOI: 10.1093/annonc/mdh430] [Cited by in Crossref: 123] [Cited by in F6Publishing: 107] [Article Influence: 7.2] [Reference Citation Analysis]
37 Lin S, Su T, Chu C, Chang Y, Yang L, Kuo Y, Huang T. Synthesis of C-4-Substituted Steviol Derivatives and Their Inhibitory Effects against Hepatitis B Virus. J Nat Prod 2016;79:3057-64. [DOI: 10.1021/acs.jnatprod.6b00671] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
38 Huang T, Chou B, Lin C, Weng J, Chou C, Yang L, Lin S. Synthesis and antiviral effects of isosteviol-derived analogues against the hepatitis B virus. Phytochemistry 2014;99:107-14. [DOI: 10.1016/j.phytochem.2013.12.014] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 2.9] [Reference Citation Analysis]
39 Motavaf M, Alavian SM. RNA interference: a promising approach for the treatment of viral hepatitis. Hepat Mon. 2012;12:7-8. [PMID: 22451837 DOI: 10.5812/kowsar.1735143X.812] [Reference Citation Analysis]
40 Cheng H, Zhang HZ, Shen WA, Liu YF, Ma FC. Expression of RNase H of human hepatitis B virus polymerase in Escherichia coli. World J Gastroenterol 2003;9:513-5. [PMID: 12632508 DOI: 10.3748/wjg.v9.i3.513] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
41 Abd El-Kader SM, Al-Dahr MH. Impact of weight reduction program on serum alanine aminotransferase activity and immunologic response in obese hepatitis B patients. Afr Health Sci 2016;16:128-34. [PMID: 27358623 DOI: 10.4314/ahs.v16i1.17] [Cited by in F6Publishing: 1] [Reference Citation Analysis]